Free Trial
NASDAQ:ZURA

Zura Bio Q1 2025 Earnings Report

Zura Bio logo
$1.04 +0.01 (+0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.06 +0.02 (+2.40%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zura Bio EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Zura Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Zura Bio Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Thursday, May 8, 2025
Conference Call Time
7:00AM ET

Zura Bio Earnings Headlines

What is HC Wainwright's Forecast for Zura Bio Q1 Earnings?
Vladimir Lenin was right…
The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.
See More Zura Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email.

About Zura Bio

Zura Bio (NASDAQ:ZURA), a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

View Zura Bio Profile

More Earnings Resources from MarketBeat